Which GLP-1 Is Best for You? Genetic & Biomarker Insights

Last reviewed: May 27, 2026

Last updated: May 27, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Selecting the right GLP-1 medication is not a one-size-fits-all decision; it requires evaluating individual metabolic status, clinical goals, tolerability factors, and emerging evidence on genetic predispositions in peptide signaling pathways. A provider-guided assessment that incorporates baseline health markers and personal risk factors significantly improves the likelihood of a therapeutic fit.

For individuals considering GLP-1 therapy, understanding how biomarkers and genetic context inform medication choice empowers more productive conversations with healthcare providers. PlexusDx emphasizes precision wellness—pairing clinical evidence with personalized insights to help you and your provider align on the most suitable therapeutic approach.

Baseline Metabolic Assessment: The Foundation of GLP-1 Selection

Before starting any GLP-1, a baseline evaluation should include fasting glucose, HbA1c, insulin levels, lipid panel, and kidney function tests. These markers reveal your metabolic state and help determine whether semaglutide, tirzepatide, or another GLP-1 agonist aligns with your clinical profile and treatment goals.

Weight-loss GLP-1 medications show distinct efficacy profiles: semaglutide reduces weight by roughly 10–17% over 68 weeks, while tirzepatide (dual GLP-1/GIP agonist) achieves 21–22% weight reduction in comparable trials. Your baseline BMI, comorbidities, and previous medication responses help guide this choice.

GLP-1 Medication Profiles: Clinical Outcomes and Mechanism Differences

GLP-1 medications vary in mechanism, onset, dosing frequency, and weight-loss efficacy. Understanding these differences—alongside your clinical history—helps providers recommend the most appropriate option. The table below summarizes key clinical distinctions.

Medication Type	Mechanism	Weight Loss Range	Dosing	Key Clinical Note
Semaglutide (GLP-1 only)	GLP-1 receptor agonist	10–17%	Weekly injection or daily oral	First-line for many; extensive cardiovascular outcome data
Tirzepatide (GLP-1/GIP dual)	GLP-1 and GIP receptor agonist	21–22%	Weekly injection	Greater weight loss; may improve lipid profile and glucose control
Microdose GLP-1 Protocol	Lower-dose GLP-1 exposure	Variable; patient-specific	Frequent small doses	Designed for side-effect tolerability; requires discipline
Oral formulations	GLP-1 receptor agonist (bioavailability-enhanced)	Comparable to injections when adherent	Daily oral	Convenient for injection-averse patients; variable absorption

Genetic Predispositions in Peptide Pathways: What the Evidence Shows

Recent research has identified genetic variants associated with differential metabolic response to GLP-1 and GIP agonists. Key variants—including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313—show predisposition patterns in appetite regulation, glucose handling, and weight-loss responsiveness. These genetic markers do not predict exact medication response but may provide clinical context for provider discussions.

Understanding your genetic predispositions in peptide pathways can support a more informed conversation about which GLP-1 candidate might align best with your metabolic profile. For example, certain FTO variants correlate with greater propensity for weight gain; combined with biomarker data, this context helps providers anticipate tolerability and efficacy expectations.

Tolerability, Side Effects, and Who Benefits Most from Each Option

Common GLP-1 side effects include nausea, vomiting, and gastrointestinal upset, especially during dose escalation. Semaglutide and tirzepatide show similar tolerability profiles overall, but individual responses vary widely. Dose adjustment, slower titration schedules, and lifestyle modifications reduce adverse events in most patients. Microdose protocols are designed for those particularly sensitive to side effects, though efficacy data are limited.

GLP-1 medications are contraindicated in personal or family history of medullary thyroid cancer, multiple endocrine neoplasia type 2, and severe pancreatitis. Kidney disease, cardiovascular history, and concurrent medications require careful provider evaluation. Oral formulations may be preferred by patients unable to tolerate injections; compounded options expand access and afford flexible dosing based on tolerability needs.

How PlexusDx Supports a More Personalized Approach

PlexusDx's Precision Peptide Genetic Test reveals predispositions across GLP-1 pathway genes—GIPR, GLP1R, FTO, and MC4R—and may help provide clinical context for your provider's medication selection. These genetic insights do not guarantee specific medication response; instead, they complement baseline biomarkers and clinical judgment to support a more personalized treatment conversation.

The genetic test costs $99 as an add-on to a PlexusDx assessment or $298 as a standalone evaluation. Results highlight your genetic predispositions in peptide metabolic pathways, which your provider can integrate alongside fasting glucose, insulin, lipid data, and weight-loss history to make an informed recommendation. This layered approach—genetic plus biomarker plus clinical—reflects current precision-medicine best practices.

Once you and your provider choose a GLP-1 candidate, PlexusDx offers compounded semaglutide injections ($149/mo), oral semaglutide ($249/mo), compounded tirzepatide injections ($249/mo), oral tirzepatide ($279/mo), and specialized protocols like Microdose GLP-1 ($129/month) and GLP-Squared dual compounds ($249/mo)—all from licensed 503A compounding pharmacies. Compounded medications allow flexible dosing and cost-effective access for patients seeking personalized GLP-1 therapy.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Oral starts at $279/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.